《滬深兩市》上證重上3,200點 深成全日升2.4% 內房及醫藥股走高
內地昨日(16日)新增本土確診病例1,226例,本土無症狀感染者1,206例。疫情驟見緩和,深圳將分區分類、有序組織企業復工復產。人民銀行今日(17日)進行800億元人民幣(下同)7天期逆回購操作,單日淨投放700億元。人民幣兌美元中間價今上調394點。
上日,國務院金融委會議強調內地資本市場穩定發展,帶動A股各指數爆升。上證深成承接上日升勢今早高開高走,上證重上3,200點水平,深成及創板升幅顯着,惟A股各指數升幅於尾市略爲收窄,上證企穩3,200點水平之上收市。
上證全日升44點或1.4%,收報3,215點;深成指全日漲289點或2.4%,收報12,289點;創業板指數升75點或2.9%,收報2,710點,成交3,268億元。上證深成全日成交顯着增加,分別爲5,325.5億元及7,429億元。
中資金融股跑輸大市,工行(601398.SH)、建行(601939.SH)倒跌收市,兩股分別跌0.7%及0.3%。
財政部稱今年內不具備擴大房地產稅改革試點城市的條件,全線地產股走高,金科股份(000656.SZ)、金地集團(600383.SH)、保利發展(600048.SH)及萬科(000002.SZ)升1.9%-8.8%。
白酒股續升,龍頭股貴州茅臺(600519.SH)及五糧液(000858.SZ)分別升2.7%及2%。
多家中藥企業產品獲納入最新新型冠狀病毒肺炎診療方案,刺激一衆中藥概念股炒上,亞寶藥業(600351.SH)、紅日藥業(300026.SZ)各揚逾6%。盤龍藥藥(002864.SZ) 及精華製藥(002349.SZ)漲停。
35家藥企獲允許免費生產輝瑞新冠口服藥,其中包括五家內地企業,刺激一衆新冠藥物概念股繼續走強,中國醫藥(600056.SH)漲停。復星醫藥(600196.SH)揚7.5%。國藥股份(600511.SH)升3.3%。公司去年淨利潤按年增長26.86%,擬10派7元。
比亞迪(002594.SZ)及寧德時代(300750.SZ)分別升2.4%及4.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.